Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

October 7, 2024

Study Completion Date

August 29, 2025

Conditions
Locally Advanced or Metastatic Solid Tumours
Interventions
DRUG

AZD0171

AZD0171

DRUG

Durvalumab

Durvalumab

DRUG

Gemcitabine

Chemotherapy (Standard-of-Care)

DRUG

Nab-paclitaxel

Chemotherapy (Standard-of-Care)

Trial Locations (34)

10065

Research Site, New York

13620

Research Site, Seongnam-si

14263

Research Site, Buffalo

22908

Research Site, Charlottesville

28027

Research Site, Madrid

28034

Research Site, Madrid

28041

Research Site, Madrid

28050

Research Site, Madrid

28222

Research Site, Majadahonda

30318

Research Site, Atlanta

31008

Research Site, Pamplona

48109

Research Site, Ann Arbor

49503

Research Site, Grand Rapids

53792

Research Site, Madison

78229

Research Site, San Antonio

83814

Research Site, Coeur d'Alene

90025

Research Site, Los Angeles

92037

Research Site, La Jolla

92868

Research Site, Orange

93003

Research Site, Ventura

97239

Research Site, Portland

98195

Research Site, Seattle

02114

Research Site, Boston

L4M 6M2

Research Site, Barrie

M4N 3M5

Research Site, Toronto

M5G 2M9

Research Site, Toronto

463-712

Research Site, Seongnam-si

03080

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

06591

Research Site, Seoul

08916

Research Site, Badalona

08035

Research Site, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY